ArticleActa neuropathologica communications2025
Melanoma antigens in pediatric medulloblastoma contribute to tumor heterogeneity and species-specificity of group 3 tumors.
Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomarkers of Treatment Response in Paediatric Medulloblastoma.Diagnostics (Basel, Switzerland) · 2026Review
- Cross-Species Upregulation ofCurrent issues in molecular biology · 2026Article
Corrections and comments
- Update of
Authors and funding
16 authors.
Funding
Abstract
Medulloblastoma (MB) is the most malignant childhood brain cancer. Group 3 MB (G3 MB) subtype accounts for about 25% of MB and is associated with the worst outcomes. Herein, we report that more than half of G3 MB tumors express melanoma antigens (MAGEs), which are potential prognostic and therapeutic markers. MAGEs are cancer-testis antigens, aberrantly expressed in several adult cancers, and associated with poorer prognosis and therapy resistance; however, their role in pediatric cancers is mostly unknown. This study aimed to determine whether MAGEs are activated and important in pediatric MB. We obtained formalin-fixed paraffin-embedded tumor samples of 34 patients, collected between 2008 and 2015 at the Children's Medical Center in Dallas and applied our validated reverse transcription quantitative PCR (RT-qPCR) assay to measure the expression of 23 MAGE genes. To validate our data, we analyzed published datasets from pediatric MB tumors and patient-derived orthotopic xenografts, totaling 949 patients. Our RT-qPCR analysis suggested that MAGEs were expressed in G3/4MB. Further mining of bulk and single-cell RNA-sequencing datasets confirmed that 50-75% of G3 tumors activate several MAGEs. Intriguingly, single-cell data analysis showed that MAGEs are expressed in distinct subsets of cells in MAGE-positive tumors and are not activated in mouse genetic models, suggesting they contribute to the tumor heterogeneity and species-specificity of G3 MB. We then examined how MAGE expression affects the growth and oncogenic potential by CRISPR-Cas9- and siRNA-mediated gene depletion. Depletion of MAGEAs, -B2, and -Cs altered cell survival, viability, and clonogenic growth due to decreased proliferation and increased apoptosis of MAGE-positive MB cells. These findings suggested that targeting MAGEs could represent a viable therapeutic strategy for G3 MB. A deeper understanding of MAGE regulation and function is warranted and could aid in improving prognostic and therapeutic approaches for this poorly characterized subgroup of pediatric brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.